Our Blog Posts

A 4-day Bench Trial is currently scheduled to commence on April 25, 2022 at 8:30 AM ET in Eagle Pharmaceuticals' Case related to its BENDEKA® product.  This is in the Case of: "Eagle Pharmaceuticals, Inc. v. Hospira, Inc." (Case #18-01074 in the District of Delaware).  Additionally, the Pretrial Conference in this Case is currently scheduled to be […]

A Hearing on the Order to Show Cause as to why Oak Pacific Investment (“OPI”) should not be restrained from Disposing (or any other related activity) of Social Finance, Inc. (“SoFi”) shares is currently scheduled to be held on Friday, May 14, 2021 at 9:30 AM ET in the Case of: “In Re RenRen, Inc. Derivative […]

On January 15, 2021, the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”) issued a Decision that DENIED Institution of a Petition for Inter Partes Review filed by Regeneron, Inc. (REGN) against a Patent Owned by Novartis (NVS).  In light of this development, this email provides an overview of Regeneron’s remaining outstanding […]

On December 8, 2020, Telephonic Oral Arguments are currently scheduled to commence at 10:00 AM ET in the Appellate Cases of: “Mylan Pharmaceuticals Inc. v. Biogen MA Inc.” (Case #20-1673 at the Court of Appeals for the Federal Circuit) and “Biogen International GmbH v. Mylan Pharmaceuticals Inc.” (Case #20-1933 at the Court of Appeals for the Federal Circuit).  This […]

On September 2, 2020, the Hearing in Teva’s “Post Grant Review” challenging Corcept’s U.S. Patent Number 10,195,214 (which covers Corcept’s Korlym product) was held before the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”).  This was in PGR2019-00048, and we now expect the PTAB to issue its Final Written Decision […]